Coats' Disease: Very Long-Term Outcome After Early Stage Conventional Treatment

Overview

Journal Open Ophthalmol J

Publisher Bentham Open

Specialty Ophthalmology

Date 2016 Mar 26

PMID 27014383

Citations 2

Authors

Salvatore Perrone

Alberto Rossetti

Patrick Sportiello

Pierfrancesco Mirabelli

Pierangela Cimatti

Daniele Doro

Affiliations

Soon will be listed here.

Abstract

Purpose: To report on the outcome of conventional therapy in patients with Coats' disease.

Methods: Retrospective analysis of the charts of thirteen patients with Coats' disease.

Results: Mean age of 9 male (70%) and 4 female (30%) patients was 17.7 (range, 5-33) years; one female had bilateral disease. Eleven eyes with retinal telangiectasia and exudation were treated with argon laser photocoagulation alone or photocoagulation associated with cryotherapy; the mean follow up was 32.5 (range,17-41) years. In four eyes without foveal involvement (stage 2a) the mean presenting visual acuity (VA) remained at 0.8 or improved, whereas poor VA in seven stage 2b eyes deteriorated minimally over time. In one and two of the three eyes with total retinal detachment, phthisis or neovascular glaucoma ensued.

Conclusion: About three decades after conventional treatment of Coats' disease stage 2a, treated eyes maintained good VA, and stage 2b eyes did not progress to advanced stages.

Citing Articles

Recent advances in the diagnosis and treatment of Coats' disease.

Yang X, Wang C, Su G Int Ophthalmol. 2019; 39(4):957-970.

PMID: 30895419 DOI: 10.1007/s10792-019-01095-8.

Optical Coherence Tomography and Optical Coherence Tomography Angiography in Monitoring Coats' Disease.

Hautz W, Golebiewska J, Kocyla-Karczmarewicz B J Ophthalmol. 2017; 2017:7849243.

PMID: 28377823 PMC: 5362730. DOI: 10.1155/2017/7849243.

References

Spitznas M, Joussen F, WESSING A, MEYER-SCHWICKERATH G . Coat's disease. An epidemiologic and Fluorescein angiographic study. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1975; 195(4):241-50. DOI: 10.1007/BF00414937. View

Smithen L, Brown G, Brucker A, Yannuzzi L, Klais C, Spaide R . Coats' disease diagnosed in adulthood. Ophthalmology. 2005; 112(6):1072-8. DOI: 10.1016/j.ophtha.2004.12.038. View

Zhao Q, Peng X, Chen F, Zhang Y, Wang L, You Q . Vascular endothelial growth factor in Coats' disease. Acta Ophthalmol. 2013; 92(3):e225-8. DOI: 10.1111/aos.12158. View

Othman I, Moussa M, Bouhaimed M . Management of lipid exudates in Coats disease by adjuvant intravitreal triamcinolone: effects and complications. Br J Ophthalmol. 2009; 94(5):606-10. DOI: 10.1136/bjo.2009.168013. View

Nucci P, Bandello F, Serafino M, Wilson M . Selective photocoagulation in Coats' disease: ten-year follow-up. Eur J Ophthalmol. 2003; 12(6):501-5. View

Shields J, Shields C, Honavar S, Demirci H . Clinical variations and complications of Coats disease in 150 cases: the 2000 Sanford Gifford Memorial Lecture. Am J Ophthalmol. 2001; 131(5):561-71. DOI: 10.1016/s0002-9394(00)00883-7. View

Char D . Coats' syndrome: long term follow up. Br J Ophthalmol. 1999; 84(1):37-9. PMC: 1723222. DOI: 10.1136/bjo.84.1.37. View

Adam R, Kertes P, Lam W . Observations on the management of Coats' disease: less is more. Br J Ophthalmol. 2006; 91(3):303-6. PMC: 1857684. DOI: 10.1136/bjo.2006.103382. View

Morris B, Foot B, Mulvihill A . A population-based study of Coats disease in the United Kingdom I: epidemiology and clinical features at diagnosis. Eye (Lond). 2010; 24(12):1797-801. DOI: 10.1038/eye.2010.126. View

10.

Ray R, Baranano D, Hubbard G . Treatment of Coats' disease with intravitreal bevacizumab. Br J Ophthalmol. 2012; 97(3):272-7. DOI: 10.1136/bjophthalmol-2012-302250. View

11.

Shields J, Shields C, Honavar S, Demirci H, Cater J . Classification and management of Coats disease: the 2000 Proctor Lecture. Am J Ophthalmol. 2001; 131(5):572-83. DOI: 10.1016/s0002-9394(01)00896-0. View

12.

Ramasubramanian A, Shields C . Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction. Br J Ophthalmol. 2011; 96(3):356-9. DOI: 10.1136/bjophthalmol-2011-300141. View

13.

Silodor S, Augsburger J, Shields J, Tasman W . Natural history and management of advanced Coats' disease. Ophthalmic Surg. 1988; 19(2):89-93. View

14.

Zheng X, Jiang Y . The effect of intravitreal bevacizumab injection as the initial treatment for Coats' disease. Graefes Arch Clin Exp Ophthalmol. 2013; 252(1):35-42. DOI: 10.1007/s00417-013-2409-1. View

15.

Budning A, Heon E, Gallie B . Visual prognosis of Coats' disease. J AAPOS. 1999; 2(6):356-9. DOI: 10.1016/s1091-8531(98)90034-9. View

16.

Mrejen S, Metge F, Denion E, Dureau P, Edelson C, Caputo G . Management of retinal detachment in Coats disease. Study of 15 cases. Retina. 2009; 28(3 Suppl):S26-32. DOI: 10.1097/IAE.0b013e31816b3158. View

17.

Schefler A, Berrocal A, Murray T . Advanced Coats' disease. Management with repetitive aggressive laser ablation therapy. Retina. 2009; 28(3 Suppl):S38-41. DOI: 10.1097/IAE.0b013e318163cd7c. View

18.

Sigler E, Randolph J, Calzada J, Wilson M, Haik B . Current management of Coats disease. Surv Ophthalmol. 2013; 59(1):30-46. DOI: 10.1016/j.survophthal.2013.03.007. View

19.

Rishi P, Rishi E, Uparkar M, Sharma T, Gopal L, Bhende P . Coats' disease: an Indian perspective. Indian J Ophthalmol. 2010; 58(2):119-24. PMC: 2854442. DOI: 10.4103/0301-4738.60081. View